myNEO

myNEO is a distinguished Belgian biotech powerhouse dedicated to pioneering breakthrough immunotherapies tailored to target diverse tumor profiles. myNEO's discovery platform leverages immuno-genomic datasets to identify tumor alterations and unveil promising and largely untapped immunotherapeutic targets. In vivo studies underscore myNEO's prowess in identifying effective tumor targets. myNEO is now advancing development of its proprietary 'camyotopes', a class of long non-coding RNAs that shows selective translation in tumor tissue and a robust immunogenic multi-targeted response against the tumor. The lead program CAMYO-01 will validate the MOA of the camyotopes in a CRC phase I/II trial, while simultaneously expanding the development pipeline to other indications.